Two Sigma Investments, LP Inhibrx, Inc. Transaction History

Two Sigma Investments, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$32.76 - $39.56 $2.31 Million - $2.79 Million	70,500 Added 892.41%	78,400 $2.74 Million
Q4 2023 Feb 14, 2024	SELL	$14.5 - $38.0 $2.9 Million - $7.59 Million	-199,770 Reduced 96.2%	7,900 $300,000
Q3 2023 Nov 14, 2023	SELL	$15.75 - $26.31 $830,812 - $1.39 Million	-52,750 Reduced 20.26%	207,670 $3.81 Million
Q2 2023 Aug 14, 2023	SELL	$16.96 - $27.82 $1.28 Million - $2.1 Million	-75,383 Reduced 22.45%	260,420 $6.76 Million
Q1 2023 May 15, 2023	BUY	$18.45 - $27.14 $1.66 Million - $2.44 Million	89,802 Added 36.5%	335,803 $6.34 Million
Q4 2022 Feb 14, 2023	BUY	$20.18 - $33.33 $1.67 Million - $2.75 Million	82,512 Added 50.47%	246,001 $6.06 Million
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $454,677 - $970,998	39,264 Added 31.61%	163,489 $2.94 Million
Q2 2022 Aug 15, 2022	BUY	$8.52 - $25.26 $566,171 - $1.68 Million	66,452 Added 115.02%	124,225 $1.41 Million
Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $1.15 Million - $2.49 Million	57,773 New	57,773 $1.29 Million
Q2 2021 Aug 16, 2021	SELL	$14.69 - $27.52 $259,836 - $486,773	-17,688 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$16.27 - $41.26 $287,783 - $729,806	17,688 New	17,688 $355,000

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $570M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.